Clinical Trial Update: Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating OCZ103-OS with standard chemotherapy in patients with unresectable, locally recurrent, or metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• OCZ103-OS

Snippet

Sponsor: Oncozyme Pharma Inc. | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED